Search the Israeli drug index

Hematinic. Iron (as Ferric carboxymaltose) 50 mg/ml.
Dispers. for inf. VIAL: 1/2/5 X 2 ml/10 ml; 1 X 20 ml
Admin. 1000 mg once/w.
Tmt. of iron defic. when oral iron preparat. are ineffective or cannot be used. The diagnosis must be based on lab. tests
C/I:  Hypersens. incl. to other  inject. iron preparations. Anemia not caused by iron defic. Iron excess or hereditary disorder in iron utilization.

Kappa Opioid Receptor Agonist. Difelikefalin 50 mcg/ml.
Sol. for IV inj. 3/12 X 1 ml
This prod. should be restricted for in-centre haemodialysis use only.
To be admin. 3 times per week by IV bolus inj. into the venous line of the dialysis circuit at the end of haemodialysis during rinse-back or after rinse-back.
Recomm. dose of difelikefalin is 0.5 microg/kg dry BW (i.e., the target postdialysis weight). The total dose volume (mL) required from the vial should be calculated as follows: 0.01 × dry body weight (kg), rounded to the nearest tenth (0.1 mL). For pts. with a dry BW equal to or above 195 kg the recomm. dose is 100 microgr (2 mL). See prescribing info.
Tmt. of moderate-to-severe pruritus associated with chronic kidney dis. in adult pts. on haemodialysis
C/I:  Hypersens.

Insulin-Like Growth Factor-1 Receptor Antagonist. Teprotumumab 500 mg/vial.
VIAL 1X 500 mg, powder for concen. for sol. for inf.
 Assess pts. for elevated blood glucose and symptoms of hyperglycemia prior to infusion and continue to monitor while on treatment with this drug. Ensure pts. with hyperglycemia or pre-existing diabetes are under appropriate glycemic ctrol. before and while receiving this drug.
Assess pts.’ hearing before, during, and after tmt. with this drug and consider the benefit-risk of tmt.
The recommended dose is an IV infusion of 10 mg/kg for the initial dose followed by an IV infusion of 20 mg/kg every three weeks for 7 additional infusions.
Tmt. of moderate to severe Thyroid Eye Disease regardless of activity and duration  
C/I:  Hypersens

Anti-VEFG, Monoclonal Antibody. Ranibizumab 10 mg/ml.
Sol. for inject.: 1 X 0.23 ml /vial
Dose in adults : 0.5 mg given as a single intravitreal inject. This corresponds to an inject. vol. of 0.05 ml. Interval between 2 doses injected into the same eye should be at least 4 weeks. See lit.
Pts. with neovascular (wet) age-related macular degeneration (AMD)
Adult pts. with visual impairment due to diabetic macular oedema (DME)
Visual impairment due to macular oedema second. to retinal vein occlusion (RVO)
Visual impairment due to choroidal neovascularization (CNV)
Proliferative diabetic retinopathy (PDR)
C/I: Hypersens.
Active or suspected ocular or periocular infections.
Active severe intraocular inflammation.

Bevacizumab 25 mg/ml.
VIALS: 1 x 100 mg/4 ml; 1 x 400 mg/16ml
Metastatic carcinoma of the colon or rectum (mCRC)
5 mg/kg or 10 mg/kg once every 2 weeks or 7.5 mg/kg or 15 mg/kg once every 3 weeks. until progression of dis. or unacceptable tox.
Metastatic breast cancer (mBC)
10 mg/kg once every 2 weeks or 15 mg/kg once every 3 weeks until progression of dis. or unacceptable tox.
Non-small cell lung cancer (NSCLC)
First-line tmt. of non-squamous NSCLC in combin. with platinum-based chemother.:
in addition to platinum-based chemother. for up to 6 cycles of tmt. followed by this drug as a sgle. agent until dis. progress. 7.5 mg/kg or 15 mg/kg once every 3 weeks. Clinical benefit in NSCLC pts. has been demonstrated with both 7.5 mg/kg and 15 mg/kg doses. until progress. of dis. or unacceptable tox.
First-line tmt. of non-squamous NSCLC with EGFR activating mutations in combin. with erlotinib:
EGFR mutation testing should be performed prior to init. of tmt with the combin. of this drug and erlotinib. It is important that a well-validated and robust methodology is chosen to avoid false neg. or false posit. determination.
15 mg/kg once every 3 weeks until dis. progress.
Advanced and/or metastatic renal cell cancer (mRCC)
10 mg/kg once every 2 weeks until progress. of the dis. or unacceptable tox.
Malignant Glioma (WHO Grade IV) - Glioblastoma
10 mg/kg once every 2 weeks or 15 mg/kg once every 3 weeks. until progress. of dis. or unacceptable tox.
Epithelial ovarian, fallopian tube and primary peritoneal cancer
Front-line tmt.:
in addition to carboplatin and paclitaxel for up to 6 cycles of tmt. followed by cont. use of this drug as sgle. agent until dis. progress or for a max. of 15 months or until unacceptable tox., whichever occurs earlier. Dose of this prod. is 15 mg/kg once every 3 weeks.
Tmt. of platinum-sensitive recurrent dis.
in combin. with carboplatin and gemcitabine for 6 cycles and up to 10 cycles followed by cont. use of this drug as sgle. agent until dis. progress. Dose is 15 mg/kg once every 3 weeks.
Tmt. of platinum-resistant recurrent dis.
In combin. with one of the following – paclitaxel, topotecan (given weekly) or pegylated liposomal doxorubicin. The dose of this drug is 10 mg/kg once every 2 weeks. When admin. in comb. with topotecan (on days 1-5, every 3 weeks), the dose of this drug is 15 mg/kg g once every 3 weeks. until dis. progress. or unacceptable tox.
Cervical Cancer
in comb. with one of the following chemother. regimens: paclitaxel and cisplatin or paclitaxel and topotecan. The dose of this drug is 15 mg/kg once every 3 weeks. until progress. of dis. or until unacceptable tox.
In comb. with fluoropyrimidine-based chemother -tmt. of pts. with metastatic carcinoma of the colon or rectum.
In comb. with paclitaxel - first-line tmt. of adlt. pts. with metastatic breast cancer.
In addition to platinum-based chemother- first-line tmt. of pts. with unresectable adv. metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
In comb. with erlotinib -first-line tmt of adlt. pts. with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.
In combin. with interferon alfa-2a - first line tmt. of pts. with adv. and/or metastatic renal cell cancer.
As a single agent, - tmt. of glioblastoma in patients with progress. dis.  following prior ther.
In combin. with carboplatin and paclitaxel - front-line tmt. of advanced ([FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at high risk for recurrence (residual disease after debulking).
In  comb. with carboplatin and gemcitabine, - tmt. of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior ther. with bevacizumab or other VEGF inhibit. or VEGF receptor-targeted agents.
In combin. with paclitaxel, topotecan, or pegylated liposomal doxorubicin – ttmt. of adult pts. with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemother. regimens and who have not received prior ther. with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
In combinat. with paclitaxel and cisplatin or, paclitaxel and topotecan, - tmt. of pts. with persistent, recurrent, or metastatic carcinoma of the cervix
C/I:  Hypersens
Hypersens. to Chinese Hamster Ovary (CHO) cell prod. or other recomb. human or humanised antibodies. Pregn.